3 news items
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
AMLX
SEEL
19 Mar 24
:
22% improvement in the slope of change in ALSFRS-R assessment adjusted for mortality, with an 89% success probability, at 24 weeks
Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005
SEEL
19 Mar 24
assessment adjusted for mortality, with an 89% success probability, at 24 weeksthe rate of decline in ALSFRS-R slope
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
SEEL
19 Mar 24
% improvement in slope of change in ALSFRS-R assessment adjusted for mortality, with an 89% success probability, at 24 weeks
- Prev
- 1
- Next